Gastrointestinal Cancer News

Three patients have been safely treated with CT-0508, a novel cell-based therapy, according to initial results of a phase 1 trial presented at Society for the Immunotherapy of Cancer Annual Meeting.

The U.S. Multi-Society Task Force on Colorectal Cancer updated its screening recommendations.

Despite a significant amount of data in the adjuvant setting for pancreatic cancer, more research is needed to better define perioperative and neoadjuvant treatment strategies, according to a speaker at Chemotherapy Foundation Symposium.

LAS VEGAS – Obesity was an independent risk factor for the development of colorectal cancer among patients who underwent weight loss surgery or who were on weight loss medication, according to a presentation.

FDA approvals of immunotherapies are among several exciting developments during the past couple of years in the field of upper gastrointestinal cancers, according to a speaker at Chemotherapy Foundation Symposium.

Pancreatic cancer often is called the silent killer.

While colorectal adenocarcinoma incidence rates are increasing in white individuals aged 40 to 49 years, they are stabilizing in Black individuals of the same age, according to results published in JAMA Network Open.

Unemployment appeared associated with a lower likelihood of having health insurance and of being up to date on cancer screening tests, according to results of a study published in Cancer.

The FDA granted fast track designation to TT-00420 for treatment of patients with cholangiocarcinoma who have no standard therapy options.

Ripretinib failed to prolong PFS compared with sunitinib among patients with gastrointestinal stromal tumor who received prior treatment with imatinib, according to results of the phase 3 INTRIGUE study released by the agent’s manufacturer.